The Wyss Institute at Harvard University announced today that Ropirio Therapeutics, Inc. (Ropirio) has secured a worldwide, exclusive license from Harvard’s Office of Technology Development (OTD) and Boston University (BU)’s Technology Development office for novel molecules that activate the lymphatic system – a first in the pharma industry.
What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today
Whether you’re a fan of the drug name Zepbound or, like one X user, think it sounds like “an off brand bus line,” you’re likely
November 20, 2023